research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-14 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
==== Barth syndrome ==== Barth syndrome is a rare genetic disorder that was recognised in the 1970s to cause infantile death. It has a mutation in the gene coding for tafazzin, an enzyme involved in the biosynthesis of cardiolipin. Tafazzin is an indispensable enzyme to synthesize cardiolipin in eukaryotes involved in the remodeling of CL acyl chains by transferring linoleic acid from PC to monolysocardiolipin. Mutation of tafazzin would cause insufficient cardiolipin remodeling. However, it appears that cells compensate and ATP production is similar or higher than normal cells. Females heterozygous for the trait are unaffected. Sufferers of this condition have mitochondria that are abnormal. Cardiomyopathy and general weakness is common to these patients.
On September 11, 2019, Chief Justice of Ontario George Strathy said that the "cuts to Legal Aid Ontario will force many people to self-represent...What we judges can say is that reducing legal representation for the most vulnerable members of society does not save money. It increases trial times, places greater demands on public services, and ultimately delays and increases the cost of legal proceedings for everyone."
== Origin == The Kalyāṇakāraka, composed in South India by Ugrāditya, is the earliest medical work to contain alchemical content. It is datable to the early ninth century CE. It gives descriptions for the processing of mercury and uses technical terminology related to the procedures and implements required for alchemy. It is the first work to describe purifying (śodhana) and calcining (māraṇaʼ) mercury for medicinal use. The first work of the Sanskrit alchemical literary genre called rasaśāstra is the 10th century Rasahṛdayatantra. The texts 19 chapters focus on the processing mercury, outlines 18 means to process mercury and discusses the transmutation of metals and the body.
== Safety == In vivo dermal sensitization studies according to OECD 429 confirmed HBTU is a moderate skin sensitizer, showing a response at 0.9 wt% in the Local Lymph Node Assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. Thermal hazard analysis by differential scanning calorimetry (DSC) shows HBTU is potentially explosive.
Sources: en.wikipedia.org
Brazil ranked 52nd in the Global Innovation Index in 2025, up from 66th in 2019. Among the most renowned Brazilian inventors are priests Bartolomeu de Gusmão, Landell de Moura and Francisco João de Azevedo, besides Alberto Santos-Dumont, Evaristo Conrado Engelberg, Manuel Dias de Abreu, Andreas Pavel and Nélio José Nicolai. Brazilian science is represented by the likes of César Lattes (Brazilian physicist Pathfinder of Pi Meson), Mário Schenberg (considered the greatest theoretical physicist of Brazil), José Leite Lopes (the only Brazilian physicist holder of the UNESCO Science Prize), Artur Avila (the first Latin American winner of the Fields Medal), and Fritz Müller (pioneer in factual support of the theory of evolution by Charles Darwin).
==== Montessori ==== Prince George's County Public Schools has implemented two facilities dedicated to the Montessori instructional program — the Robert Goddard Montessori School and the John Hanson Montessori School. As dedicated facilities, these schools do not have a neighborhood attendance area. Entry into the program is through the random lottery application process only. The Montessori Primary Program for children ages 3 to 6 years old is based on the Montessori educational philosophy. Taught by Montessori accredited teachers, young children are guided in developing an inner discipline, strengthening their coordination, and extending their concentration span. These accomplishments result with their readily learning to read, write and grasp mathematics. The program consists of a half-day morning for preschoolers (ages 3 ). Children older than four must be enrolled in a certified Montessori program to be accepted into the program. The Montessori Lower Elementary Program is designed for students ages 6 to 9 years old with prior Montessori experience. Rapid growth and learning is observed in classrooms filled with appropriate educational materials. The Montessori Upper Elementary Program continues for the next age grouping of students ages 9–12 with prior Montessori experience. Taught by Montessori accredited teachers, these elementary program students study an integrated curriculum that includes: mathematics, geometry, language, cultural studies, astronomy, biology, chemistry, geography, history, geology, philosophy, art, music and physical education.
== Outtakes == The songs "Fear the Voices" and "Lying Season" were featured on Alice in Chains' 1991 demo tape that featured songs from Sap and Dirt. Both of these songs were later included on the band's 1999 box set, Music Bank. "Fear the Voices" was released as a single in 1999 to promote Music Bank and became a radio hit that same year. Regarding the two songs, Cantrell said that they came from a time when the band was still developing its sound.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.